Genmab A/S
GMABNASDAQHealthcare● Active
$24.98
$-0.18(-0.70%)
Market Cap$15.3B
P/E Ratio—
52W High$35.43
52W Low$20.225
Genmab A/S (GMAB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GMAB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.15
Est. $0.15 · +0.0%
Revenue
$0.90B
Est. $0.91B · -1.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
GMAB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.34 | — | — | — | $1.09B | — |
| — Q2 FY2026 | May 7, 2026 | $0.15 | $0.15 | +0.0% | $0.90B | $0.91B | -1.1% |
| ▼ Q1 FY2026 | Feb 17, 2026 | $0.46 | $0.05 | -89.1% | $1.06B | $1.07B | -0.8% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.48 | $0.65 | +35.4% | $1.02B | $1.01B | +1.1% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.39 | $0.54 | +38.5% | $0.92B | $0.95B | -2.9% |
| ▲ Q2 FY2025 | May 8, 2025 | $0.23 | $0.31 | +34.8% | $0.73B | $0.76B | -3.9% |
| ▲ Q1 FY2025 | Feb 12, 2025 | $0.28 | $0.57 | +103.6% | $0.89B | $0.79B | +12.6% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $0.35 | $0.29 | -17.1% | $0.82B | $0.81B | +0.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.34
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026
EPS Actual
$0.15
EPS Est.
$0.15
EPS Surpr.
+0.0%
Revenue
$0.90B
Q1 FY2026
Feb 17, 2026Miss
EPS Actual
$0.05
EPS Est.
$0.46
EPS Surpr.
-89.1%
Revenue
$1.06B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.65
EPS Est.
$0.48
EPS Surpr.
+35.4%
Revenue
$1.02B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.54
EPS Est.
$0.39
EPS Surpr.
+38.5%
Revenue
$0.92B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$0.31
EPS Est.
$0.23
EPS Surpr.
+34.8%
Revenue
$0.73B
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
$0.57
EPS Est.
$0.28
EPS Surpr.
+103.6%
Revenue
$0.89B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
$0.29
EPS Est.
$0.35
EPS Surpr.
-17.1%
Revenue
$0.82B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.81 | $0.87 | $0.95 | 2 |
| Q3 FY2028 | $0.71 | $0.76 | $0.84 | 2 |
| Q2 FY2028 | $0.59 | $0.64 | $0.70 | 2 |
| Q1 FY2028 | $0.45 | $0.48 | $0.53 | 2 |
| Q4 FY2027 | $0.52 | $0.56 | $0.61 | 1 |
| Q3 FY2027 | $0.45 | $0.48 | $0.53 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.6B | $1.7B | $1.8B | 6 |
| Q3 FY2028 | $1.5B | $1.5B | $1.7B | 3 |
| Q2 FY2028 | $1.3B | $1.4B | $1.5B | 5 |
| Q1 FY2028 | $1.2B | $1.2B | $1.3B | 3 |
| Q4 FY2027 | $1.4B | $1.4B | $1.5B | 7 |
| Q3 FY2027 | $1.2B | $1.3B | $1.4B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +0.0% | $27.89 | $27.06 | -2.98% |
| ▼ Q1 FY2026 | Feb 17, 2026 | -89.1% | $30.03 | $30.00 | -0.10% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +35.4% | $29.19 | $28.84 | -1.20% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +38.5% | $21.51 | $22.69 | +5.49% |
| ▲ Q2 FY2025 | May 8, 2025 | +34.8% | $20.60 | $19.42 | -5.73% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +103.6% | $18.89 | $19.69 | +4.24% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -17.1% | $22.75 | $22.33 | -1.85% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -24.1% | $26.46 | $27.07 | +2.31% |
Q2 FY2026-2.98%
Report Date
May 7, 2026
EPS Beat/Miss
+0.0%
Price Before
$27.89
Price After
$27.06
Q1 FY2026-0.10%
Report Date
Feb 17, 2026
EPS Beat/Miss
-89.1%
Price Before
$30.03
Price After
$30.00
Q4 FY2025-1.20%
Report Date
Nov 6, 2025
EPS Beat/Miss
+35.4%
Price Before
$29.19
Price After
$28.84
Q3 FY2025+5.49%
Report Date
Aug 7, 2025
EPS Beat/Miss
+38.5%
Price Before
$21.51
Price After
$22.69
Q2 FY2025-5.73%
Report Date
May 8, 2025
EPS Beat/Miss
+34.8%
Price Before
$20.60
Price After
$19.42
Q1 FY2025+4.24%
Report Date
Feb 12, 2025
EPS Beat/Miss
+103.6%
Price Before
$18.89
Price After
$19.69
Q4 FY2024-1.85%
Report Date
Nov 6, 2024
EPS Beat/Miss
-17.1%
Price Before
$22.75
Price After
$22.33
Q3 FY2024+2.31%
Report Date
Aug 8, 2024
EPS Beat/Miss
-24.1%
Price Before
$26.46
Price After
$27.07
Avg Beat Reaction-0.04%
Avg Miss Reaction+0.12%
Beat Rate5 / 8 quarters
Largest Move-5.73% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GMAB ends December
Genmab A/S (GMAB) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.15 (in line with the analyst consensus of $0.15). The next GMAB earnings date is expected around September 1, 2026.
Each quarter, investors track GMAB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GMAB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GMAB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GMAB earnings · 4 questionsGenmab A/S's next earnings report is expected around September 1, 2026. GMAB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GMAB historically reports after market close (AMC).
GMAB earnings datewhen is GMAB earningsGMAB next earnings datewhen does GMAB report earningsGMAB earnings calendar
▸ Source: FMP · Genmab A/S SEC filings · US GAAP · Genmab A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026